Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

PURPOSE Conventional-dose chemotherapy (CDCT) and high-dose chemotherapy (HDCT) may both be successfully used as salvage treatment for patients with metastatic germ cell tumors (GCTs) who experience progression with first-line treatment. PATIENTS AND METHODS Data on 1,984 patients with GCTs who experienced progression after at least three cisplatin-based cycles and were treated with either cisplatin-based CDCT or carboplatin-based HDCT chemotherapy were collected from 38 centers or groups worldwide. Of 1,984 patients, 1,594 (80%) were eligible, and among the eligible patients, 1,435 (90%) could reliably be classified into one of the following five prognostic categories based on prior prognostic classification: very low (n = 76), low (n = 257), intermediate (n = 646), high (n = 351), and very high risk (n = 105). Within each of the five categories, the progression-free survival (PFS) and overall survival (OS) after CDCT and HDCT were compared using the Cox model adjusted for significant distributional differences between important variables. RESULTS Overall, 773 patients received CDCT, and 821 patients received HDCT. Both treatment modalities were used with similar frequencies within each prognostic category. The hazard ratio for PFS was 0.44 (95% CI, 0.39 to 0.51) stratified on prognostic category, and the hazard ratio for OS was 0.65 (95% CI, 0.56 to 0.75), favoring HDCT. These results were consistent within each prognostic category except among low-risk patients, for whom similar OS was observed between the two treatment groups. CONCLUSION This retrospective analysis suggests a benefit from HDCT given as intensification of first salvage treatment in male patients with GCTs and emphasizes the need for another prospective randomized trial comparing CDCT to HDCT in this patient population.

[1]  Andrew Kramar,et al.  Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Bokemeyer,et al.  High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  S. Perkins,et al.  High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. , 2007, The New England journal of medicine.

[4]  J. Bacik,et al.  Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Siegert,et al.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  L. Einhorn,et al.  Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Siegert,et al.  High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Bains,et al.  Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Einhorn,et al.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Huhn,et al.  High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Tricot,et al.  Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[13]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .